Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: A population-based study

Annals of Surgical Oncology

Volumn 18, Issue 10, 2011, Pages 2988-2996

  Abdollah, Firas ^a,b   Sun, Maxine ^a   Thuret, Rodolphe ^a,c   Schmitges, Jan ^a,d   Shariat, Shahrokh F ^e   Perrotte, Paul ^a   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MORTALITY; NEPHRECTOMY; POSTOPERATIVE COMPLICATION;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FLORIDA; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORBIDITY; NEPHRECTOMY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE;

EID: 80052783771     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1715-2     Document Type: Article

References (28)

1. NCCN (2010) NCCN clinical practice guidelines in oncology. Kidney cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
2. RC Flanigan SE Salmon BA Blumenstein, et al. 2001 Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med. 345 1655 1659 11759643 10.1056/NEJMoa003013 1:CAS:528:DC%2BD3MXovFKjt74%3D (Pubitemid 33126820)
3. GH Mickisch A Garin H van Poppel, et al. 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet. 358 966 970 11583750 10.1016/S0140-6736(01)06103-7 1:CAS:528:DC%2BD3MXntF2qtbw%3D (Pubitemid 32913522)
4. RC Flanigan G Mickisch R Sylvester, et al. 2004 Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol. 171 1071 1076 14767273 10.1097/01.ju.0000110610.61545.ae (Pubitemid 38327529)
5. RT Bennett SE Lerner HC Taub, et al. 1995 Cytoreductive surgery for stage IV renal cell carcinoma J Urol. 154 32 34 7776449 10.1016/S0022-5347(01)67217-3 1:STN:280:DyaK2M3psFSqsw%3D%3D
6. ML Fallick DF McDermott D LaRock, et al. 1997 Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma J Urol. 158 1691 1695 9334580 10.1016/S0022-5347(01)64097-7 1:CAS:528:DyaK1cXmsVOrt7c%3D (Pubitemid 27433133)
7. DA Levy DA Swanson JW Slaton, et al. 1998 Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma J Urol. 159 1168 1173 9507824 10.1016/S0022-5347(01)63542-0 1:STN:280:DyaK1c7mslansA%3D%3D (Pubitemid 28172786)
8. MM Walther RB Alexander GH Weiss, et al. 1993 Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma Urology. 42 250 257 8379024 10.1016/0090-4295(93)90612-E 1:STN:280: DyaK3szpt1altQ%3D%3D (Pubitemid 23270929)
9. MM Walther JC Yang HI Pass, et al. 1997 Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma J Urol. 158 1675 1678 9334576 10.1016/S0022-5347(01)64091-6 1:CAS:528:DyaK1cXmsVOrt7k%3D (Pubitemid 27433129)
10. SF Matin LT Madsen CG Wood 2006 Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience Urology. 68 528 532 16979706 10.1016/j.urology.2006.03.076 (Pubitemid 44436519)
11. MA Goetzl ET Goluboff AM Murphy, et al. 2004 A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival Urol Oncol. 22 182 187 15271312 10.1016/j.urolonc.2004.02.001 (Pubitemid 38950622)
12. V Margulis SF Matin N Tannir, et al. 2008 Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol. 180 94 98 18485389 10.1016/j.juro.2008.03.047
13. Florida Health Finder. http://www.floridahealthfinder.gov/researchers/ researchers.aspx. Accessed 14 June 2010.
14. Statistics. Hysterectomy hospitalizations, 1993-2002. Health outcome series. 2004, p 5. http://edocs.dlis.state.fl.us/fldocs/ahca/Hoseries/ hysterectomy-hospitalizations2004.pdf.
15. PS Romano LL Roos JG Jollis 1993 Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives J Clin Epidemiol. 46 1075 1079 8410092 10.1016/0895-4356(93)90103-8 1:STN:280:DyaK2c%2FhsFWrsw%3D%3D (Pubitemid 23302074)
16. FN Joudi V Allareddy CJ Kane, et al. 2007 Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample J Urol. 177 1709 1714 17437791 10.1016/j.juro.2007.01.037 (Pubitemid 46560669)
17. C Jeldres S Baillargeon-Gagne D Liberman, et al. 2009 A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States Urology. 74 837 841 19616828 10.1016/j.urology. 2009.04.019
18. L Budaus M Sun F Abdollah, et al. 2011 Impact of surgical experience on in-hospital complication rates in patients undergoing minimally invasive prostatectomy: a population-based study Ann Surg Oncol. 18 839 847 20953720 10.1245/s10434-010-1300-0
19. BR Konety V Allareddy H Herr 2006 Complications after radical cystectomy: analysis of population-based data Urology. 68 58 64 16806414 10.1016/j.urology.2006.01.051 (Pubitemid 44037723)
20. SM Alibhai M Leach G Tomlinson 2008 Impact of hospital and surgeon volume on mortality and complications after prostatectomy J Urol. 180 155 162 18485382 10.1016/j.juro.2008.03.040
21. CB Begg ER Riedel PB Bach, et al. 2002 Variations in morbidity after radical prostatectomy N Engl J Med. 346 1138 1144 11948274 10.1056/NEJMsa011788 (Pubitemid 34984605)
22. JC Hu Q Wang CL Pashos, et al. 2008 Utilization and outcomes of minimally invasive radical prostatectomy J Clin Oncol. 26 2278 2284 18467718 10.1200/JCO.2007.13.4528
23. PA Clavien JR Sanabria SM Strasberg 1992 Proposed classification of complications of surgery with examples of utility in cholecystectomy Surgery. 111 518 526 1598671 1:STN:280:DyaK383osFygsA%3D%3D
24. AG Lawthers EP McCarthy RB Davis, et al. 2000 Identification of in-hospital complications from claims data. Is it valid? Med Care 38 785 795 10929991 10.1097/00005650-200008000-00003 1:STN:280:DC%2BD3czpslymtQ%3D%3D
25. CARMENA. Randomized phase III trial evaluating the importance of nephrectomy in patients presenting with metastatic renal cell carcinoma treated with sunitinib. http://clinicaltrials.gov/ct2/show/NCT00930033?term= renal+cancer&recr=Open&intr=nephrectomy&rank=2 (2009).
26. EORTC. Randomized Phase III trial comparing presurgical sunitinib followed by nephrectomy and sunitinib versus nephrectomy followed by sunitinib in patients with synchronous metastatic renal cell carcinoma. http://www.eortc.be/protoc/Details.asp?Protocol=30073&T= (2008, updated February 2010).
27. R Halbert R Figlin M Atkins, et al. 2006 Treatment of patients with metastatic renal cell cancer Cancer. 107 2375 2383 17048248 10.1002/cncr.22260 1:CAS:528:DC%2BD28XhtlantL3F (Pubitemid 44748520)
28. RE Mitchell BT Lee MS Cookson, et al. 2009 Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48, 000 patients BJU Int. 104 1442 1445 19681895 10.1111/j.1464-410X. 2009.08794.x